This is the lay version of the EULAR recommendations for the management of people with a type of vasculitis associated with an antibody called antineutrophil cytoplasmic antibody. This name of this disease is often shortened to ANCA-associated vasculitis, or AAV. The original publication can be downloaded from the EULAR website: www.eular.org. Hellmich B, Sanchez-Alamo B, […]
Category: ANCA-associated vasculitis
Mycophenolate mofetil achieves remission in AAV
MMF is non-inferior to cyclophosphamide for achieving remission in people AAV, but results in higher relapse rate. Introduction ANCA-associated vasculitis (shortened to AAV), is a rare group of diseases that are very serious, and can be life-threatening. These diseases are linked to a type of autoantibody called ANCA. An antibody is a protein that the […]
Tailored treatment may be a possibility for AAV in people with GPA or MPA
AAV relapse rates did not significantly differ between individually tailored and fixed schedule rituximab regimens. Introduction Granulomatosis is a medical term for a disease where granulomas – or clusters of certain cell types – are formed. This can happen in immune or inflammatory diseases. People can have with granulomatosis with polyangiitis (also known as Wegener’s […]
Newly updated advice on the treatment of patients with AAV
INTRODUCTION A central focus of newly updated recommendations on treating ANCA-associated vasculitis (AAV) is shared decision-making between patients and doctors. The updated recommendations, produced by a collaboration between the European League Against Rheumatism (EULAR) and European Renal Association – European Dialysis and Transplant Association (ERA-EDTA), taking account of recent research on the benefits and safety […]
